Saniona CEO Thomas Feldthus and board member Carl Johan Sundberg purchase Saniona shares in the open market
06 Julho 2022 - 3:00AM
Saniona CEO Thomas Feldthus and board member Carl Johan Sundberg
purchase Saniona shares in the open market
PRESS RELEASE
July
6, 2022
Saniona (OMX: SANION), a clinical stage
biopharmaceutical company, today announced that
the CEO and a member of
the Board of Directors
have purchased
240,221
shares of the company in the open market for a total value
of approximately SEK
0.9
million.
Saniona CEO Thomas Feldthus bought 200,221 shares in the company
for a total investment of SEK 785,683. Saniona board member Carl
Johan Sundberg bought 40,000 shares in the company for a total
investment of SEK 142,128. All transactions have been made in the
open market during the period from July 1 to July 5, 2022.
For more information, please contact Thomas
Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com
This information was submitted for publication, through the
agency of the contact person set out above, at 08.00 CEST on July
6, 2022.
About Saniona Saniona is a clinical-stage
biopharmaceutical company with a mission to leverage its ion
channel targeting expertise to discover, develop and deliver
innovative rare disease treatments. The company’s most advanced
product candidate, Tesomet™, has been progressed into mid-stage
clinical trials for hypothalamic obesity and Prader-Willi syndrome,
serious rare disorders characterized by severe weight gain,
disturbances of metabolic functions and uncontrollable hunger.
Saniona has developed a proprietary ion channel drug discovery
engine anchored by IONBASE™, a database of more than 130,000
compounds, of which more than 20,000 are Saniona’s proprietary ion
channel modulators. Through its ion channel expertise, Saniona is
advancing two wholly owned ion channel modulators, SAN711, SAN903.
SAN711 has successfully completed a Phase 1 clinical trial and is
positioned for the treatment of neuropathic pain conditions; SAN903
is in preclinical development for rare inflammatory, fibrotic, and
hematological disorders. Saniona is based in the Copenhagen area,
Denmark, and is listed on Nasdaq Stockholm Small Cap (OMX: SANION).
Read more at http://www.saniona.com.
- 20220706 Saniona Insider purchase release (UK)
Saniona Ab (LSE:0RQJ)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Saniona Ab (LSE:0RQJ)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
